BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 17559740)

  • 1. Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States.
    Jhaveri M; Seal B; Pollack M; Wertz D
    Curr Med Res Opin; 2007 Jun; 23(6):1431-43. PubMed ID: 17559740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of zolpidem extended release in elderly primary insomnia patients.
    Walsh JK; Soubrane C; Roth T
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):44-57. PubMed ID: 18165461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms.
    Barkin RL
    Am J Ther; 2007; 14(3):299-305. PubMed ID: 17515707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
    Asche CV; Joish VN; Camacho F; Drake CL
    Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study.
    Voshaar RC; van Balkom AJ; Zitman FG
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):301-6. PubMed ID: 15163440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight weeks of non-nightly use of zolpidem for primary insomnia.
    Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
    Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic insomnia treatment and Medicare Part D: implications for managed care organizations.
    Navarro R; Mitrzyk BM; Bramley TJ
    Am J Manag Care; 2007 Nov; 13(5 Suppl):S121-4. PubMed ID: 18041872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.
    Staner L; Eriksson M; Cornette F; Santoro F; Muscat N; Luthinger R; Roth T
    Sleep Med; 2009 Jun; 10(6):616-20. PubMed ID: 18996742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics of insomnia therapy: implications for policy.
    Botteman M
    Sleep Med; 2009 Sep; 10 Suppl 1():S22-5. PubMed ID: 19647482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey data, 1997-2002.
    Morlock RJ; Tan M; Mitchell DY
    Clin Ther; 2006 Jul; 28(7):1044-53. PubMed ID: 16990083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indiplon: a nonbenzodiazepine sedative-hypnotic for the treatment of insomnia.
    Marrs JC
    Ann Pharmacother; 2008 Jul; 42(7):1070-9. PubMed ID: 18594049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison.
    Jacobs GD; Pace-Schott EF; Stickgold R; Otto MW
    Arch Intern Med; 2004 Sep; 164(17):1888-96. PubMed ID: 15451764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia--assessment of a novel intervention strategy in a primary care setting.
    Hajak G; Bandelow B; Zulley J; Pittrow D
    Ann Clin Psychiatry; 2002 Mar; 14(1):1-7. PubMed ID: 12046635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
    Dorsey CM; Lee KA; Scharf MB
    Clin Ther; 2004 Oct; 26(10):1578-86. PubMed ID: 15598474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indiplon in older adults with primary insomnia.
    Walsh JK; Moscovitch A; Burke J; Farber R; Roth T
    Sleep Med; 2007 Nov; 8(7-8):753-9. PubMed ID: 17825616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
    Lydiard RB; Lankford DA; Seiden DJ; Landin R; Farber R; Walsh JK
    J Clin Sleep Med; 2006 Jul; 2(3):309-15. PubMed ID: 17561543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.
    Krystal AD; Huang H; Zummo J; Grinnell T; Marshall RD
    Sleep Med; 2012 Jun; 13(6):691-6. PubMed ID: 22465450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.